Arndt Rolfs, MD, Professor for Neurology and Psychiatry, is appointed CEO and founder of Centogene AG, and Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock, Germany. He received his approbation for human medicine in 1985 from the University of Mainz, Germany and the University of Vienna, Austria. Arndt is a principle investigator of several international multicentre studies in the area of rare diseases and actively engaged in biomarker research for several metabolic diseases. Arndt is a principal investigator of several international multicenter studies in the area of rare diseases, including the Sifap project (www.sifap.eu), the world's largest study in young stroke patients related to Fabry disease, several biomarker studies (e.g. BioHAE, BioGaucher, BioHunter, BioMorquio) and epidemiological studies in neurogenetic aetiologies. Arndt has an extensive track record in medical and scientific publications with more than authored/contributed to 250 peer-reviewed publications and acts as a consultant for international biotech and industrial companies, and is also a consultant for the EMA and FDA.